Nast A, Smith C, Spuls P I, Avila Valle G, Bata-Csörgö Z, Boonen H, De Jong E, Garcia-Doval I, Gisondi P, Kaur-Knudsen D, Mahil S, Mälkönen T, Maul J T, Mburu S, Mrowietz U, Reich K, Remenyik E, Rønholt K M, Sator P G, Schmitt-Egenolf M, Sikora M, Strömer K, Sundnes O, Trigos D, Van Der Kraaij G, Yawalkar N, Dressler C
Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
St John's Institute of Dermatology, London, UK.
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2461-2498. doi: 10.1111/jdv.16915.
This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.
本基于证据和共识的寻常型银屑病治疗指南是依据欧洲皮肤病学指南和共识声明制定手册制定的。该指南的第一部分包括关于范围和目的、涵盖的健康问题、目标用户以及指南的优势/局限性的一般信息。提供了疾病严重程度分级和治疗目标的建议。它给出了一般治疗建议以及针对个别药物的详细管理和监测建议。本指南中讨论的治疗选择如下：阿维A、环孢素、富马酸盐、甲氨蝶呤、阿达木单抗、阿普米司特、布罗达单抗、赛妥珠单抗、依那西普、古塞库单抗、英夫利昔单抗、司库奇尤单抗、瑞莎珠单抗、苏金单抗、替拉珠单抗和乌司奴单抗。
